Abdul Jaber Tayem

Abdul Jaber Tayem

Auto-generated profile, based on publicly available information

Abdul Jaber Tayem

Visual Outcomes Lab, Department of Neurology Cedars Sinai Medical Center Los Angeles California USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Therapeutic Advances in Cardiovascular Disease
Verified
Journal Article
Open access
AHAbdulrahman Khaldoon Hamid
Abdulrahman Khaldoon Hamid
ATAbdulJaber A’Ed Tayem
AbdulJaber A’Ed Tayem
SASandra Thair Al-Aish
Sandra Thair Al-Aish
ASAhmed Sermed Al Sakini
Ahmed Sermed Al Sakini
DHDalia Dhia Hadi
Dalia Dhia Hadi
RARami Thair Al-Aish
Rami Thair Al-Aish
Background: Heart failure (HF) is a highly prevalent disease, among the primary factors contributing to morbidity and death. One of its types is heart failure with preserved ejection fraction (HFpEF) comprising 40%–50% of newly diagnosed HF cases. Despite the high prevalence of HFpEF, there is still a lack of knowledge regarding the best drugs and treatment approaches to be used. However, the sodium-glucose co-transporter 2 (SGLT2) inhibitors could be a promising treatment. Objectives: To examine SGLT2 inhibitors’ effect on hospitalization, cardiovascular death, and estimated glomerular filtration rate (eGFR) in HFpEF patients. Search methods: We conducted searches for randomized controlled trials (RCTs) in PubMed, Embase, Scopus, and Web of Science up to July 2024. Selection criteria: We chose RCTs that examined the effects of SGLT2 inhibitors and placebo in individuals with higher than 40% ejection fraction (HFpEF). Data collection and analysis: The methodology for the systematic review and meta-analysis was in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis. Main results: We included 8 studies with 16,509 participants. Drugs examined in our paper included empagliflozin, dapagliflozin, sotogliflozin, and ertugliflozin. Various outcomes were analyzed in different papers. However, different SGLT2 inhibitors lead to a decreased risk of cardiovascular hospitalization and kidney injury. Our meta-analysis showed a decreased risk of cardiovascular hospitalization but not death due to cardiovascular causes or other causes. These results were regardless of baseline status of eGFR, systolic blood pressure, atrial fibrillation or flutter, diabetes mellitus, sex, body mass index, and nt-proBNP. The included studies were of moderate to high quality. Conclusion: For individuals with HFpEF, SGLT2 inhibitors have been proven to be a safe and effective medication. However, more studies are needed for longer durations, reporting adverse events, effects on exercise tolerance, and other secondary outcomes.

13 March 2026 in Journal of Alzheimer’s Disease
Verified
Journal Article
Open access
ATAbdul Jaber Tayem
Abdul Jaber Tayem
AJAhmad Bani Jaber
Ahmad Bani Jaber
AAAhmad M. Altantawi
Ahmad M. Altantawi
NMNoor M. Masadeh
Noor M. Masadeh
LQLaith Al Quran
Laith Al Quran
FIFor The Alzheimer'S Disease Neuroimaging Initiative
For The Alzheimer'S Disease Neuroimaging Initiative
Background: Alzheimer's disease (AD) is the most common form of dementia, marked by progressive cognitive decline. Low-density lipoprotein cholesterol (LDL-C) has been implicated in AD pathology, but findings remain inconsistent. Apolipoprotein E4 (APOE4) status and sex may contribute to this variability. Objective: To examine how LDL-C association with neurodegeneration in AD patients, differ according to APOE4 status and gender. Methods: We stratified 106 AD patients by APOE4 status and sex into four subgroups: male APOE4+, female APOE4+, male APOE4−, and female APOE4−. Longitudinal cortical thickness changes were assessed using magnetic resonance imaging (MRI). We examined the association between LDL-C levels and cortical thinning within each subgroup. Results: In APOE4-positive females, higher LDL-C levels were significantly associated with accelerated cortical thinning in several regions, including the parahippocampal (β = −0.0075, p = 0.017), medial orbitofrontal (β = −0.0025, p = 0.028), fusiform (β = −0.0047, p = 0.034), posterior cingulate (β = −0.0097, p = 0.006), and inferior temporal cortices (β = −0.0085, p = 0.019). This subgroup also showed a significant association between LDL-C and MMSE decline (β = −1.409, p = 0.014) as well as longitudinal increases in cerebrospinal fluid phosphorylated tau181 (β = 0.014, p = 0.039). These effects were not observed in other subgroups. Conclusions: Elevated LDL-C is associated with increased neurodegeneration and cognitive decline in female AD patients carrying the APOE4 allele. These exploratory findings highlight a subgroup-specific vulnerability to lipid-related neurodegeneration in AD and underscore the importance of considering both sex and genetic background in future studies.

17 March 2026 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
ATAbdul Jaber Tayem
Abdul Jaber Tayem
ALAngel Liu
Angel Liu
SMSargis Manukyan
Sargis Manukyan
MSMustafa Subhi
Mustafa Subhi
ELElaina Luskin
Elaina Luskin
OAOmar Al‐Louzi
Omar Al‐Louzi
Objectives: Retrograde trans‐synaptic degeneration (rTSD) from posterior visual pathway lesions in multiple sclerosis (MS) is characterized by hemi‐macular ganglion cell‐inner plexiform layer (GCIPL) thinning and contralateral visual field loss. We investigated associations between rTSD, paramagnetic rim lesions (PRL), and longitudinal visual disability in people with MS (pwMS) using a novel optical coherence tomography (OCT) based biomarker of rTSD. Methods: PwMS, non‐MS neurological disease controls, and healthy controls underwent OCT, multiparametric brain MRI, and clinical assessments. A quantitative rTSD index was developed to capture hemispheric GCIPL asymmetry, with absolute values reflecting rTSD severity. Generalized linear models were used to investigate MRI and clinical predictors of rTSD. Longitudinal changes in rTSD were evaluated using mixed‐effects linear regression models. Results: A total of 170 pwMS and 49 controls were included. PwMS had higher rTSD than healthy ( p = 0.006) and non‐MS controls ( p = 0.009). African American race ( p = 0.02) and longer disease duration ( p = 0.005) were associated with higher baseline rTSD. PRL in the optic radiations (OR) was linked to a 4.5‐fold increase in rTSD ( p = 0.037; n = 37) and −1.18 dB reduction in hemifield sensitivity ( p = 0.018). Longitudinally, each unit/year progression in rTSD was associated with a −0.07 dB/year decline in hemifield sensitivity ( p = 0.005) and a 10.8‐fold increase in the odds of expanded disability status scale score progression ( p = 0.022). Higher body mass index was associated with faster rTSD progression longitudinally ( p = 0.02). Interpretation: PRL in the OR, African American race, disease duration, and higher BMI are associated with rTSD in pwMS. Longitudinal increase in rTSD is associated with worsening visual loss and clinical disability progression in MS. Trial Registration: ClinicalTrials.gov identifier: NCT05204459